+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure



Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure



Cardiovascular Drugs and Therapy 24(1): 49-60



Beta-blockers are mainstay of current treatment of heart failure (HF). Beta-adrenergic receptors (AR) single nucleotide gene polymorphisms (SNPs) may influence the sensitivity and density of beta-AR. We assessed the relation between three common beta-AR SNPs and the response to carvedilol administration. We studied 183 consecutive patients with chronic HF due to ischemic or nonischemic cardiomyopathy, a LV ejection fraction (LVEF) < or = 0.35, not previously treated with beta-blockers. Each patient underwent gated-SPECT radionuclide ventriculography, cardiopulmonary exercise testing and invasive hemodynamic monitoring at baseline and after 12 months of carvedilol administration at maintenance dosages. The beta1-AR gene Arg389Gly and the beta2-AR gene Arg16Gly SNPs were not related to the response to carvedilol administration. Homozygotes for the Glu27Glu allele showed a greater increase in the LVEF, compared to the other patients (+13.0 +/- 12.2% versus +7.1 +/- 8.1% in the Gln27Gln homozygotes, and 8.3 +/- 11.4% units in the Gln27Glu heterozygotes; p = 0.022 by ANOVA). Glu27Glu homozygotes also showed a greater decline in the pulmonary wedge pressure both at rest and at peak exercise. Gln27Glu SNP was selected amongst the determinants of the LVEF response to carvedilol at multivariable analysis, in addition to the cause of cardiomyopathy, baseline systolic blood pressure and the dose of carvedilol administered. Beta1-AR Arg389Gly and beta2-AR Arg16Gly SNPs are not related to the response to carvedilol therapy. In contrast, the Gln27Glu SNP is a determinant of the LVEF response to this agent in patients with chronic HF.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055601532

Download citation: RISBibTeXText

PMID: 20352314

DOI: 10.1007/s10557-010-6220-5


Related references

Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenetics and Genomics 15(3): 137-142, 2005

Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. British Journal of Clinical Pharmacology 71(4): 556-565, 2011

Effects of long-term beta-adrenergic receptor blockade on body weight in cachectic and non-cachectic patients with chronic heart failure. Circulation 106(19 Suppl.): II 685, 2002

Beta-2 adrenergic receptors polymorphisms influence the effects of carvedilol in the patients with chronic heart failure. Circulation 108(17 Suppl.): IV-485-IV-486, 2003

Effects of long-term beta-adrenergic blockade on exercise capacity in patients with chronic heart failure. Balady, G J, Pina, I L American Heart Association Monograph Series; Exercise and heart failure: 141-170, 1997

Long-term effects of heart rate reduction in patients with heart failure Comparison with chronic beta-adrenergic blockade. Journal of the American College of Cardiology 33(2 Suppl. A): 189A, 1999

Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET. Current Heart Failure Reports 1(2): 82-88, 2004

Which component of the beta adrenergic pathway best reflects the hemodynamic and clinical response to long term beta blockade in chronic heart failure?. Circulation 84(4 Suppl.): II469, 1991

Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol). American Journal of Cardiology 92(5): 548-553, 2003

Polymorphisms of the beta-2 adrenergic receptors may influence the effects of beta-blocker therapy in the patients with chronic heart failure. European Heart Journal 24(Abstract Suppl.): 711, August-September, 2003

The link between acute haemodynamic adrenergic beta-blockade and long-term effects in patients with heart failure. A study on diastolic function, heart rate and myocardial metabolism following intravenous metoprolol. European Heart Journal 14(10): 1375-1385, 1993

Serum autoantibodies against the cardiac beta(1)-adrenergic receptor in patients with chronic heart failure: clinical characteristics and response to carvedilol. Zhonghua Xin Xue Guan Bing Za Zhi 35(7): 599-602, 2007

Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. Journal of Cachexia Sarcopenia and Muscle 8(4): 549-556, 2017

Can intravenous beta-blockade predict long-term hemodynamic benefit in chronic congestive heart failure secondary to ischemic heart disease? A comparison of intravenous with oral carvedilol. Journal of Cardiovascular Pharmacology 19(Suppl. 1): S62-S67, 1992

Can intravenous beta blockade predict long-term haemodynamic benefit in chronic congestive heart failure secondary to ischaemic heart disease? A comparison between intravenous and oral carvedilol. Clinical Investigator 70(Suppl. 1): S98, 1992